The Effect of Cellulose Phosphate on Intestinal Absorption and Urinary Excretion of Calcium: Some Experience in its use in the Treatment of Calcium Stone Formation

1974 ◽  
Vol 46 (4) ◽  
pp. 385-392 ◽  
Author(s):  
N. J. BLACKLOCK ◽  
M. A. MACLEOD
1980 ◽  
Vol 123 (1) ◽  
pp. 9-13 ◽  
Author(s):  
U. Backman ◽  
B.G. Danielson ◽  
G. Johansson ◽  
S. Ljunghall ◽  
B. Wikström

Science ◽  
1942 ◽  
Vol 96 (2504) ◽  
pp. 587-588 ◽  
Author(s):  
E. SHORR ◽  
T. P. ALMY ◽  
M. H. SLOAN ◽  
H. TAUSSKY ◽  
V. TOSCANI

2014 ◽  
pp. 1955 ◽  
Author(s):  
Akram Hossain ◽  
Ikuko Tsukamoto ◽  
Fuminori Yamaguchi ◽  
Yuko Hirata ◽  
Youyi Dong ◽  
...  

1978 ◽  
Vol 54 (5) ◽  
pp. 509-516 ◽  
Author(s):  
J. M. Baumann ◽  
S. Bisza ◽  
H. Fleisch ◽  
M. Wacker

1. The short- and longer-term effects of ethane-1-hydroxy-1,1-diphosphonate (EHDP), an inhibitor of crystal growth and potential preventive agent against urinary tract stones in man, have been studied. 2. Measurement of urinary excretion of EHDP was used to define the best dosage regimen. When 4·4 mmol of EHDP was given daily in four divided doses the urinary concentration of EHDP achieved was high enough (10−5 mol/l) to inhibit the crystallization of calcium crystals throughout the day. 3. Nine patients with recurrent calcium stones were given this dose of EHDP daily for 12 months and seven were then studied for a further 12 months under placebo. During treatment with EHDP, inhibitory activity in urine towards precipitation of calcium phosphate was restored from low values to greatly above normal. This could be accounted for by the inhibitory effect of EHDP itself, coupled with an increase in urinary inorganic pyrophosphate. After stopping EHDP the excretion of EHDP rapidly fell to undetectable levels but the excretion of pyrophosphate remained elevated throughout the 12 months of placebo treatment. EHDP also induced a rise in plasma phosphate and an increase in the urinary excretion of oxalic acid and uric acid, but these changes were all fully reversible when EHDP was stopped. 4. The average rate of stone formation per patient per year decreased from 2·4 to 0·2 during treatment with EHDP and remained low during the following 24 months. However, the dose needed for this effect is known to affect bone turnover and mineralization.


1987 ◽  
Vol 243 (1) ◽  
pp. 75-78 ◽  
Author(s):  
C Lidor ◽  
M S Meyer ◽  
R H Wasserman ◽  
S Edelstein

Decreased intestinal absorption of Ca2+ occurs in response to treatment with disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP). The effect is due to decreased 1-hydroxylation of calcidiol (25-hydroxycholecalciferol) in the kidney. In an attempt to establish whether impairment of vitamin D metabolism at steps beyond kidney hydroxylation occurs due to treatment with EHDP, chicks were depleted of vitamin D and were treated with calcitriol (1,25-dihydroxycholecalciferol) as their sole source of the vitamin. The chicks were then divided into two groups, one being treated with EHDP while the second group served as control. Intestinal absorption of Ca2+ in the EHDP-treated group was found to be impaired, along with decreases in concentrations of calbindin D28K (the 28,000-Mr vitamin D-dependent Ca2+-binding protein). When the chicks were dosed with [3H]calcitriol, significantly lower concentrations of the sterol were detected in the duodena of EHDP-treated birds. Measurement of levels of receptors for calcitriol in duodena showed no difference between groups, but levels of calcitriol in sera were considerably lower in the EHDP-treated group along with the elevated biliary and urinary excretion of glucuronidated conjugates. It is therefore concluded that treatment with EHDP results in increased catabolism of calcitriol in addition to the known suppression of the renal production of the hormone.


Sign in / Sign up

Export Citation Format

Share Document